Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer

Prostate cancer (PC) is the most common non-cutaneous malignancy affecting men in the United States, accounting for one-quarter of new cancer diagnoses in American men with 180,890 estimated new cases in 2016 [1]. Standard initial treatment for metastatic PC is androgen-deprivation therapy (ADT) with/without docetaxel chemotherapy; however, most patients receiving ADT progress to metastatic castration-resistant prostate cancer (mCRPC), characterized by cancer progression despite low serum testosterone levels.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2qL6Izx
via IFTTT